{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-096673","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.517579+00:00","generated_at":"2026-05-31T09:23:23.687940+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Metagenomi declares MGX-001 DC for hemophilia A; cash $299.9M into 2027","bullets":["Declared MGX-001 as lead development candidate for hemophilia A; 12-month NHP data accelerated to September 2024.","Cash, cash equivalents and marketable securities of $299.9M at June 30, 2024; runway into 2027.","R&D expense $28.3M in Q2 2024 vs $22.7M in Q2 2023; G&A expense $8.6M vs $6.6M.","All four Ionis Wave 1 cardiometabolic programs in lead optimization; targeting 1–2 DC nominations in 2025.","Deprioritizing PH1 and ALS programs; pipeline guidance revised through year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-096673","json":"https://secwatch.observer/filing/0000950170-24-096673.json","markdown":"https://secwatch.observer/filing/0000950170-24-096673.md","text":"https://secwatch.observer/filing/0000950170-24-096673.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/0000950170-24-096673-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/mgx-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:23:23.687940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}